These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 26476139)

  • 1. Bench to bedside: NK cells and control of metastasis.
    Krasnova Y; Putz EM; Smyth MJ; Souza-Fonseca-Guimaraes F
    Clin Immunol; 2017 Apr; 177():50-59. PubMed ID: 26476139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of Metastasis by NK Cells.
    López-Soto A; Gonzalez S; Smyth MJ; Galluzzi L
    Cancer Cell; 2017 Aug; 32(2):135-154. PubMed ID: 28810142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosurveillance and immunotherapy of tumors by innate immune cells.
    Iannello A; Thompson TW; Ardolino M; Marcus A; Raulet DH
    Curr Opin Immunol; 2016 Feb; 38():52-8. PubMed ID: 26686774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells.
    Tu MM; Mahmoud AB; Wight A; Mottashed A; Bélanger S; Rahim MM; Abou-Samra E; Makrigiannis AP
    Cancer Res; 2014 Jul; 74(14):3684-94. PubMed ID: 24802191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of natural killer cells in cancer therapy.
    Lee SK; Gasser S
    Front Biosci (Elite Ed); 2010 Jan; 2(2):380-91. PubMed ID: 20036886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.
    Chan CJ; Andrews DM; McLaughlin NM; Yagita H; Gilfillan S; Colonna M; Smyth MJ
    J Immunol; 2010 Jan; 184(2):902-11. PubMed ID: 20008292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cell receptors as tools in cancer immunotherapy.
    Sentman CL; Barber MA; Barber A; Zhang T
    Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
    Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
    J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of tumor cells escaping from immune surveillance of NK cells.
    Ge Z; Wu S; Zhang Z; Ding S
    Immunopharmacol Immunotoxicol; 2020 Jun; 42(3):187-198. PubMed ID: 32223464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cell-mediated immunosurveillance of human cancer.
    Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
    Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of NK cells.
    Yang Q; Goding SR; Hokland ME; Basse PH
    Immunol Res; 2006; 36(1-3):13-25. PubMed ID: 17337762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NK cells-directed therapies target circulating tumor cells and metastasis.
    Dianat-Moghadam H; Mahari A; Heidarifard M; Parnianfard N; Pourmousavi-Kh L; Rahbarghazi R; Amoozgar Z
    Cancer Lett; 2021 Jan; 497():41-53. PubMed ID: 32987138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
    Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
    Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell tolerance licensing and other mechanisms.
    Jonsson AH; Yokoyama WM
    Adv Immunol; 2009; 101():27-79. PubMed ID: 19231592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological targeting of natural killer cells for cancer immunotherapy.
    Miyazato K; Hayakawa Y
    Cancer Sci; 2020 Jun; 111(6):1869-1875. PubMed ID: 32301190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside.
    Woan KV; Miller JS
    Cancer Immunol Res; 2019 Nov; 7(11):1742-1747. PubMed ID: 31676567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.